Back to Faculty
Co-Chair

Jacqueline Barrientos

MD, MS
Chief Hematology Malignancies
Mount Sinai Medical Center

Jacqueline C. Barrientos, MD, is Attending Physician at the Chronic Lymphocytic Leukemia (CLL) Research & Treatment Program in Lake Success, New York. She is Associate Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.
Dr. Barrientos completed her internship and residency in medicine at Yale-New Haven Hospital, and her fellowship in Hematology/Oncology at Weill Cornell in New York City. During fellowship, she completed a Masters degree in Clinical Investigation at Weill Cornell Graduate School of Medical Sciences. She is board certified in hematology and oncology. She is the recipient of several awards including the American Society of Hematology Harold Amos Medical Faculty Development Program Award. Dr. Barrientos is Principal Investigator on several clinical trials involving targeted agents in CLL and lymphoma.

2027 Sessions

New Approval: Sonrotoclax, the Next-Gen BCL2 Inhibitor in CLL

Speaker

Saturday, February 06 11:55–12:15 PM
Room King Ballroom 3
Co-Chair

Jacqueline Barrientos

MD, MS
Chief Hematology Malignancies
Mount Sinai Medical Center

Jacqueline C. Barrientos, MD, is Attending Physician at the Chronic Lymphocytic Leukemia (CLL) Research & Treatment Program in Lake Success, New York. She is Associate Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.
Dr. Barrientos completed her internship and residency in medicine at Yale-New Haven Hospital, and her fellowship in Hematology/Oncology at Weill Cornell in New York City. During fellowship, she completed a Masters degree in Clinical Investigation at Weill Cornell Graduate School of Medical Sciences. She is board certified in hematology and oncology. She is the recipient of several awards including the American Society of Hematology Harold Amos Medical Faculty Development Program Award. Dr. Barrientos is Principal Investigator on several clinical trials involving targeted agents in CLL and lymphoma.
Back to top